Dade Behring’s New Dimension(R) Lynx System Provides Automation Solutions to Laboratories; Benefits of Automation without the Complexity and Space Requirement
Building on the success of the Dimension(R) RxL Max(TM) Integrated System, Dade Behring (NASDAQ:DADE) announced today that it is offering a new, scalable automation solution, Dimension(R) Lynx System, targeted at medium-volume laboratories. The Dimension(R) Lynx System will be showcased at the American Association for Clinical Chemistry in Orlando, Florida.
This new system utilizes the revolutionary design of the Dimension(R) RxL Max(TM) analyzer with the integration of a sample management module for increased performance and productivity. The integration is achieved by the combination of two Dimension(R) RxL Max(TM) systems, and the sample management module. The automation solution is also available with the combination of a Dimension(R) analyzer and the IMMULITE(R) 2000 or 2500 Immunoassay System.(1)
The time and cost saving advantages of the Dimension(R) Lynx System include the following:
— Smart sample management, true clot detection, sample integrity checks for HIL, sample sorting and mapping, and automated intelligent routing to eliminate the technicians guesswork
— A single operator interface for the complete system
— Automatic add-on testing without operator intervention
— Consistency in processing on two instruments
— Improved turn-around-time
— Convenient decapping capability for multiple tube sizes
“The availability of an appropriate automation solution for medium-sized laboratories will be extremely valuable for workflow management,” said Rick Lee, Senior Vice President, Marketing, Dade Behring. “In addition to its flexibility, the Dimension(R) Lynx System provides the on-board capacity to run 182 methods concurrently, providing the laboratory increased productivity and performance.”
“The features offered to customers on the Dimension(R) Lynx System demonstrate our commitment to providing innovative solutions to our customers that are relevant to their real needs,” said Jim Reid-Anderson, Chairman, President and CEO, Dade Behring. “We are committed to helping our customers improve their ability to deliver the highest quality results in an environment where resources–time, staff and funds–are limited.”
With 2004 revenues of nearly $1.6 billion, Dade Behring is the world’s largest company dedicated solely to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of labs, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the internet at www.dadebehring.com .
(1) IMMULITE(R) 2000 and IMMULITE(R) 2500 Immunoassay Systems are registered trademarks of Diagnostics Products Corporation (DPC).
